COMP <GO>
CING vs CRBP // FREE CASH FLOW YIELD
Cingulate Inc. (NASDAQ) VS. Corbus Pharmaceuticals Holdings Inc. (NASDAQ) • 15-METRIC TALLY: CING 1
— CRBP 1
■ METRIC PARITY
LAST: $4.72 (-6.16%) • MKT CAP: $73.1M
fcf-yield
-23.06%
LAST: $3.87 (-1.15%) • MKT CAP: $75.7M
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CING VS. CRBP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CING | CRBP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -23.06% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 22.3 | +30.80 | CING | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $73.1M | $75.7M | -$2.6M | CRBP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CING REV | CRBP REV | CING GROSS % | CRBP GROSS % | CING FCF | CRBP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $55.8M | $238.9M | — | — | -$17.4M | -$64.5M |
| FY 2024 | $43.8M | $136.4M | — | — | -$18.7M | -$41.8M |
| FY 2023 | $63.7M | $126.2M | — | — | -$15.0M | -$36.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CING // BETA —
CRBP // BETA —